November 28, 2014 News by Patricia Silva, PhD Diagnostic System by Luoxis Can Detect Oxidative Stress in MS Luoxis Diagnostics, Inc. recently presented three clinical and preclinical findings that feature the company’s proprietaryĀ RedoxSYSā¢ Diagnostic System as a comprehensive, groundbreaking tool for research capable of assessing a patient’sĀ oxidation-reduction potential (ORP) in the event ofĀ injury, illness, or stress.Ā The findings were presented as peer-reviewed posters during the recently concludedĀ …
November 26, 2014 News by Patricia Silva, PhD Rare Brain Infection Death Spurs FDA To Update Warning Label for MS Drug The US Food and Drug Administration has just issued a report warning the general public and healthcare providers dealing with multiple sclerosis that one of theĀ leading medications for the disease, Tecfidera (dimethyl fumarate), has been identified a possible factor in the death of an MS patient,…
November 25, 2014 News by Charles Moore Province Of Ontario Funds Genzyme’s AUBAGIO For Relapsing Remitting Multiple Sclerosis With 100,000 Canadians living with Multiple Sclerosis (MS), and three people newly diagnosed every day, Canada has one of the highest prevalence rates for the disease in the world. Most people are diagnosed with relapsing MS in their twenties and thirties, and MS is the most common neurological disease affecting…
November 24, 2014 News by admin Newly Identified Immune Cell Sheds Light on Multiple Sclerosis Cause Researchers from the National University of Singapore have found a new type of immune cell that could aid in the development of treatments for multiple sclerosis (MS). The study was published on November 21 in the journalĀ Cell ResearchĀ entitled, “STAT5 programs a distinct subset of GM-CSF-producing T helper…
November 24, 2014 News by Patricia Silva, PhD Experimental Drug for RRMS, SPMS Enters Phase 2 Trial Lexington, MA-based biopharmaceutical companyĀ Xenetic Biosciences, Inc.Ā has just announced its new license partnerĀ Pharmsynthez has completed dosing in its ongoing Phase 2 clinical trial with pipeline product MyeloXenā¢ forĀ relapsing remitting and secondary progressive (SPMS) multiple sclerosis. The MyeloXen trial is currently underway in Russia with…
November 24, 2014 by Maureen Newman New Mouse Model Better Represents JC Virus That Infects MS Patients Researchers in the laboratory of Steve Goldman, MD, PhD, Co-Director of University of Rochester Center for Translational Neuromedicine, are delving deeper into the science behind progressive multifocal leukoencephalopathy (PML), a disease caused by the JC virus, which commonly affects multiple sclerosis patients and others with compromised immune…
November 21, 2014 News by Patricia Silva, PhD Major MS Cognitive Rehabilitation Trial Funded by British Health Service TheĀ Cognitive Rehabilitation for Attention and Memory trial (CRAMMS), a major study to be conducted on patients suffering from multiple sclerosis, was recently awardedĀ Ā£1,167,000 ($1,828,000) by the British National Health ServiceĀ (NHS), through its Health Technology Assessment (HTA) Program. The study, which is expected to be the largest trial of its…
November 21, 2014 News by Patricia Silva, PhD Individualized Multiple Sclerosis CE Plan Wins Excellence Award The Alliance for Continuing Education in the Health Professions, an international membership association of healthcareĀ education professionals, has just selected the winner for theĀ 2015 Outstanding CE Enduring Material by the Alliance for Continuing Education in the Health Professions. The winner is a joint CE activity entitled, “Confronting Current Challenges…
November 20, 2014 News by Patricia Silva, PhD Alliance for Childrenās Therapeutics Expands Research to Include MS The Alliance for Childrenās TherapeuticsĀ recently announced its plans to broaden its scope of research programs to include several diseases, namely, inflammatory bowel disease (IBD), asthma, and multiple sclerosis (MS) ā a progressive, neurodegenerative disease that is estimated to affect 300,000…
November 19, 2014 News by Isaura Santos ‘Treat Me Right’ MS Society Campaign Shortlisted For Award TheĀ Treat Me RightĀ campaign from the MSĀ SocietyĀ in the UK was recentlyĀ shortlistedĀ for this year’s voluntary sector campaignĀ Public Affairs Award. The campaign was launched in April 2014 during MS Week to raise awareness for the importance of providing the right treatment at the right moment…
November 19, 2014 News by Patricia Inacio, PhD Experimental Multiple Sclerosis Drug Effectively Induces Remyelination in Pre-clinical Study In a poster session at the Annual meeting of the Society for Neuroscience in Washington,Ā ENDECE Neural presented pre-clinical results showing their lead drug ā NDC-1308 ā induces remyelination in mouse models of demyelination disease, such as Multiple Sclerosis. Loss of myelin is the main characteristic of a group…
November 18, 2014 News by Patricia Silva, PhD Home Exterior Company Remodels and Repairs MS Patient’s Home for Free For those with Multiple Sclerosis, the progressive manner in which the disease slowly deteriorates motor function, balance, and coordination can make home maintenance an impossibility. Add to this the well-documented issues that MS patients have with finding and keeping jobs and very quickly the cost and effort to maintain…
November 18, 2014 News by Patricia Silva, PhD Neurologist Recommends MS Approach Based on Alternative Medicine Unconventional medical approaches and lifestyle changes may help patients suffering from multiple sclerosis (MS) improve their health and well-being, according toĀ Allen Bowling, MD, PhD, an internationally recognized neurologist and specialist in alternative medicine. The physician has designed a seven-step method based on his expertise, which is presented on his…
November 17, 2014 News by Charles Moore Genzyme’s Lemtrada Approved by the FDA Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…
November 17, 2014 News by Maureen Newman Limb Spasm Treatments for MS Patients Explored by Flex Pharma and Ipsen Biopharmaceuticals Upper limb spasticity and lower leg cramps and spasms, two conditions that affect patients with multiple sclerosis, are being treated in separate clinical trials with results from both showing positive benefits. Dysport (abobotulinumtoxinA), from Ipsen Biopharmaceuticals, Inc., and transient receptor potential (TRP) activators, from…
November 17, 2014 News by Patricia Silva, PhD Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone Teva Pharmaceutical Industries Ltd., the company that developed the injectable multiple sclerosis treatment Copaxone (Glatiramer acetate), Ā has announced their pursuit of regulatory approval in Japan. This development comes a year after signing an agreement with Takeda Pharmaceutical Co. Ltd. According to a…
November 14, 2014 News by Isaura Santos Will It Be Possible To Predict Good And Bad Days For Multiple Sclerosis Patients? Highmark Blue Cross Blue Shield is trying to assess the possibility of predicting good and bad days for people suffering with multiple sclerosis (MS) and help them to achieve a higher quality of life. The four-week pilot program enrolled almost 100 participants that wore a body sensor patch,…
November 14, 2014 News by Charles Moore Sailboat Crewed by MS Patients Circumnavigating the Globe Oceans of Hope, a 67-foot sail yacht currently docked at North Cove Marina, New York, is on a round-the-world voyage to become the first ship to ever circumnavigate with a crew of people who have Multiple Sclerosis. The voyage, initiated by Sailing Sclerosis Foundation, set sail from Copenhagen, Denmark…
November 13, 2014 News by Charles Moore New Microparticle Secondary Progressive MS Therapy Dosing Tested In Australian Clinical Trial New Zealand and Australia-based Innate Immunotherapeutics Limited, a medical biotechnology company with offices in Sydney and Auckland, has issued an update regarding its Phase 2B trial for secondary progressive multiple sclerosis (SPMS) and other recent activities. The Phase 2B MIS416 trial Patient dosing with MIS416…
November 13, 2014 News by Patricia Silva, PhD Multiple Sclerosis Association of America Launches New Patient Support Website One of the country’s leading non-profit multiple sclerosis organizations, the Multiple Sclerosis Association of America (MSAA), has just launched a new patient support website called, My MS Journey. It is a comprehensive online resource designed to answer the specific and varied needs of MS patients, whether they have…
November 12, 2014 News by Patricia Inacio, PhD Use of Del-1 Protein Reduces Multiple Sclerosis Severity in Mouse Study In a study entitled āDevelopmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelinationā the authors report to have found a new protein, Del-1, that reduces the severity of multiple sclerosis disease in a mouse model of the disease. The…
November 12, 2014 News by Patricia Silva, PhD Inability to Recognize and Convey Emotion a Symptom of MS What may be overlooked in relating to and caring for patients with multiple sclerosis is the fact that the neurodegenerative disease sometimes affects a person’s ability to properly convey and perceive emotion. According to the National Multiple Sclerosis Society (NMSS), while there is not…
November 11, 2014 News by Patricia Inacio, PhD Obesity Linked To Multiple Sclerosis? A team of researchers at the Tel Aviv University report the role of obesity as a major risk factor triggering and maintaining autoimmune diseases, such as Crohn’s Disease and multiple sclerosis. The study was published in Autoimmunity Reviews. In autoimmune diseases, the immune system reacts against the body…
November 10, 2014 News by Patricia Silva, PhD MS Patients Being Evaluated as Fit to Work, Receiving Lower Benefits, Charities Alert Patients who suffer from progressive conditions, such as multiple sclerosis (MS), are submitted to unnecessary evaluations for disability benefits and often denied the full payment of their out-of-work benefits or deemed as fit to work when they are in fact not able. This new perspective was highlighted by a…
November 7, 2014 News by Patricia Silva, PhD Biogen Idec Gives $1.4M to New MS Research Program in Alberta Photo From University of Alberta The company behind FDA-approved multiple sclerosis drug AVONEXĀ® (Interferon beta-1a), Biogen Idec, together with the government of the province of Alberta, has…
November 5, 2014 News by Patricia Silva, PhD Teva and Active Biotech Expand Investigational MS Treatment Program Drug manufacturersĀ Teva Pharmaceutical Industries Ltd.Ā and Active Biotech announced that they expanding the ongoing clinical research program for the study ofĀ laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating theĀ ARPEGGIO trial. In addition, Teva has also announced…
November 5, 2014 News by Patricia Silva, PhD Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient Sanofi subsidiary and rare disease treatment specialistĀ GenzymeĀ has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug forĀ relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…
November 4, 2014 News by Patricia Silva, PhD National MS Society Grants $457,921 to Kessler Foundation Researcher The National Multiple Sclerosis SocietyĀ recently awarded MS researcher Lauren Strober, PhD from the Kessler Foundation, a three-year grant for her investigational research, totaling $457,921. The funding is part of a multi-site study that will be conducted by the investigator to understand the influence that having…
November 4, 2014 News by Patricia Inacio, PhD MRIs are Revealing Multiple Sclerosis in Patients, Even Before Symptoms Begin A study entitled āLongitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosisā published in the International Journal of MS Care reports that asymptomatic patients accompanied by Magnetic Resonance Images suggestive of…
November 3, 2014 News by Charles Moore Vitamin D Deficiency Found Highly Prevalent Across the Board in MS, Neuromuscular Disease A study presented at the 61st annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) held October 29 to November 1 in Savannah, Georgia, further corroborates growing awareness of a high prevalence of vitamin D deficiency in neuromuscular disease.’ The study, entitled “…